SI3584252T1 - Antigeni, vektorji, sestavki virusa človeške imunske pomanjkljivosti in postopki njihove uporabe - Google Patents

Antigeni, vektorji, sestavki virusa človeške imunske pomanjkljivosti in postopki njihove uporabe

Info

Publication number
SI3584252T1
SI3584252T1 SI201631333T SI201631333T SI3584252T1 SI 3584252 T1 SI3584252 T1 SI 3584252T1 SI 201631333 T SI201631333 T SI 201631333T SI 201631333 T SI201631333 T SI 201631333T SI 3584252 T1 SI3584252 T1 SI 3584252T1
Authority
SI
Slovenia
Prior art keywords
vectors
compositions
methods
immunodeficiency virus
human immunodeficiency
Prior art date
Application number
SI201631333T
Other languages
English (en)
Slovenian (sl)
Inventor
Johannes Petrus Maria Langedijk
Benoit C. S. CALLENDRET
Manen Danielle Van
Anders Krarup
Jorn Stitz
Frank Wegmann
Jort Vellinga
Original Assignee
Janssen Vaccines & Prevention B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention B.V. filed Critical Janssen Vaccines & Prevention B.V.
Publication of SI3584252T1 publication Critical patent/SI3584252T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SI201631333T 2015-12-15 2016-12-15 Antigeni, vektorji, sestavki virusa človeške imunske pomanjkljivosti in postopki njihove uporabe SI3584252T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15200138 2015-12-15
EP16194124 2016-10-17
EP19186284.6A EP3584252B1 (en) 2015-12-15 2016-12-15 Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof

Publications (1)

Publication Number Publication Date
SI3584252T1 true SI3584252T1 (sl) 2021-11-30

Family

ID=57737697

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201630480T SI3390430T1 (sl) 2015-12-15 2016-12-15 Antigeni virusa humane imunske pomanjkljivosti, vektorji, sestavki in postopki njihove uporabe
SI201631333T SI3584252T1 (sl) 2015-12-15 2016-12-15 Antigeni, vektorji, sestavki virusa človeške imunske pomanjkljivosti in postopki njihove uporabe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201630480T SI3390430T1 (sl) 2015-12-15 2016-12-15 Antigeni virusa humane imunske pomanjkljivosti, vektorji, sestavki in postopki njihove uporabe

Country Status (30)

Country Link
US (3) US10369214B2 (enExample)
EP (3) EP3964569A1 (enExample)
JP (2) JP6510149B2 (enExample)
KR (1) KR20180086207A (enExample)
CN (2) CN114686495A (enExample)
AU (2) AU2016369326B2 (enExample)
BR (1) BR112018011122A2 (enExample)
CA (1) CA3008542C (enExample)
CY (2) CY1122705T1 (enExample)
DK (2) DK3390430T3 (enExample)
EA (1) EA038974B1 (enExample)
ES (2) ES2753854T3 (enExample)
HR (2) HRP20191902T1 (enExample)
HU (2) HUE045993T2 (enExample)
IL (1) IL259942B2 (enExample)
LT (2) LT3390430T (enExample)
MA (3) MA47522B1 (enExample)
MD (2) MD3390430T2 (enExample)
ME (1) ME03545B (enExample)
MX (2) MX383507B (enExample)
PH (1) PH12018501047A1 (enExample)
PL (2) PL3390430T3 (enExample)
PT (1) PT3390430T (enExample)
RS (2) RS62360B1 (enExample)
SG (2) SG11201804411TA (enExample)
SI (2) SI3390430T1 (enExample)
SM (2) SMT201900629T1 (enExample)
TW (2) TWI707039B (enExample)
WO (1) WO2017102929A1 (enExample)
ZA (1) ZA201803978B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3197489T (lt) 2014-09-26 2021-07-26 Beth Israel Deaconess Medical Center, Inc. Būdai ir kompozicijos, skirti indukuoti apsauginį imunitetą prieš žmogaus imunodeficito viruso infekciją
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
EP3031923A1 (en) * 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
RS62360B1 (sr) 2015-12-15 2021-10-29 Janssen Vaccines & Prevention Bv Antigeni, vektori i sastavi virusa humane imunodeficijencije, i postupci njihove primene
EP3471765B1 (en) 2016-06-16 2024-04-24 Janssen Vaccines & Prevention B.V. Hiv vaccine formulation
US10307477B2 (en) 2016-09-02 2019-06-04 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
MX2019002938A (es) 2016-09-15 2019-10-15 Janssen Vaccines & Prevention Bv Mutaciones estebilizantes de trimeros de proteinas de la envoltura del vih.
ES2976495T3 (es) * 2017-06-15 2024-08-02 Janssen Vaccines & Prevention Bv Vectores poxvirus que codifican antígenos del VIH y métodos de uso de los mismos
JP7253529B2 (ja) * 2017-07-19 2023-04-06 ヤンセン ファッシンズ アンド プリベンション ベーフェー 三量体安定化ｈｉｖエンベロープタンパク質変異
WO2019055888A1 (en) 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. METHODS OF INDUCING AN IMMUNE RESPONSE AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN SUBJECTS UNDER ANTIRETROVIRAL TREATMENT
TW201922800A (zh) * 2017-11-17 2019-06-16 美商格里佛診斷方法股份有限公司 新穎哺乳動物表現的人類免疫缺乏病毒外套膜蛋白抗原
CN114269363A (zh) * 2019-04-17 2022-04-01 威斯达研究所 用于hiv疫苗应用的复制缺陷型腺病毒载体
WO2020237052A1 (en) 2019-05-22 2020-11-26 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
KR20220092896A (ko) 2019-11-07 2022-07-04 얀센 백신스 앤드 프리벤션 비.브이. 단백질 정제
AU2021270777A1 (en) 2020-05-12 2022-11-10 Janssen Vaccines & Prevention B.V. Administration of homologous adenoviral vectors
WO2021249011A1 (en) * 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Hiv vaccine compositions, methods, and uses thereof
WO2022006095A2 (en) * 2020-06-29 2022-01-06 Duke University Mosaic hiv-1 envelopes to induce adcc responses
US20220118081A1 (en) 2020-10-20 2022-04-21 Janssen Vaccines & Prevention B.V. HIV vaccine regimens
AU2022224967A1 (en) 2021-02-23 2023-07-27 Janssen Vaccines & Prevention B.V. Trimer stabilizing hiv envelope protein mutation
US20230000973A1 (en) * 2021-06-25 2023-01-05 Janssen Vaccines & Prevention B.V. Combinations of Vaccines and Neutralizing Antibodies for Treating Human Immunodeficiency Virus Infection in Subjects Undergoing Antiretroviral Treatment
WO2023242155A1 (en) 2022-06-14 2023-12-21 Janssen Vaccines & Prevention B.V. Compositions and methods for the diagnosis of hiv infection

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US5298416A (en) 1989-01-18 1994-03-29 British Technology Group Ltd. Attenuated polioviruses
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6083716A (en) 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US5761893A (en) 1996-10-22 1998-06-09 Lofquist Welding, Inc. Crop saving attachment for the snouts of combines
DK1550722T3 (da) 1999-05-17 2007-10-08 Crucell Holland Bv Rekombinant human adenovirus serotype 35
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6710173B1 (en) 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
WO2001019958A2 (en) * 1999-09-17 2001-03-22 Dana-Farber Cancer Institute, Inc. Stabilized soluble glycoprotein trimers
PT1335987E (pt) 2000-11-23 2006-05-31 Bavarian Nordic As Variante do virus vacina modificado ancara
CA2785699A1 (en) * 2001-07-05 2003-01-16 Novartis Vaccines And Diagnostics, Inc. Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
WO2003004657A1 (en) * 2001-07-05 2003-01-16 Chiron Corporation Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
JP4500049B2 (ja) 2001-12-04 2010-07-14 バヴァリアン・ノルディック・アクティーゼルスカブ フラビウイルスｎｓ１サブユニットワクチン
WO2004001032A2 (en) 2002-04-25 2003-12-31 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
BR0308783A (pt) 2002-04-25 2005-01-04 Crucell Holland Bv Vetor de adenovìrus recombinante, método para produzir um vetor de adenovìrus recombinante, composição farmacêutica, método para tratar um corpo humano, e, kit de partes
AU2003291402A1 (en) 2002-11-07 2004-06-03 Beth Israel Deaconess Medical Center MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
WO2004050856A2 (en) 2002-12-03 2004-06-17 University Of Massachusetts Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
EP2371380A1 (en) 2003-03-28 2011-10-05 The Government of the United States of America, represented by The Secretary, Department of Health and Human Services MVA expressing modified hiv envelope, gag, and pol genes
WO2005027840A2 (en) 2003-09-15 2005-03-31 Chiron Corporation Combination approaches for generating immune responses
WO2005052119A2 (en) 2003-11-19 2005-06-09 Beth Israel Deaconess Medical Center Adjuvants of immune response
ATE449105T1 (de) 2004-01-23 2009-12-15 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
US20070207166A1 (en) * 2004-04-12 2007-09-06 Genvec, Inc. Method of Using Adenoviral Vectors to Induce an Immune Response
WO2006002079A2 (en) 2004-06-15 2006-01-05 Progenics Pharmaceuticals, Inc. Hiv-1 neutralizing antibodies elicited by trimeric hiv-1 envelope glycoprotein complex
CA2573702C (en) * 2004-07-16 2013-10-15 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Vaccine constructs and combination of vaccines designed to improve the breadth of the immune response to diverse strains and clades of hiv
WO2006026667A2 (en) * 2004-08-27 2006-03-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant mva viruses expressing glade a/g, clade b, and clade c modified hiv, gag and pol genes
BRPI0516048A (pt) 2004-10-13 2008-08-19 Crucell Holland B V E Beth Isr batelada de um adenovìrus recombinante defectivo em replicação baseado em um sorotipo do subgrupo c
CN101588813A (zh) * 2005-04-12 2009-11-25 杜克大学 诱导人类免疫缺陷病毒的中和抗体的方法
US20100221241A1 (en) 2005-07-06 2010-09-02 University Of Maryland Biotechnology Institute Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites
US8119140B2 (en) 2005-08-23 2012-02-21 Los Alamos Security, LLC Immunogenic compositions comprising human immunodeficiency virus (HIV) mosaic Nef proteins
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
EP2040747A4 (en) 2006-06-19 2010-08-25 Progenics Pharm Inc SOLUBLE STABILIZED TRIMERS HIV CREAM PROTEINS AND ITS USE
WO2008063331A2 (en) 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
US20080279879A1 (en) 2006-11-17 2008-11-13 New York University INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE
MX2009009342A (es) 2007-03-02 2009-09-11 Glaxosmithkline Biolog Sa Metodo novedoso y composiciones.
SMT202000101T1 (it) 2008-10-10 2020-03-13 Childrens Medical Center Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
PT2358757T (pt) 2008-11-18 2018-12-04 Beth Israel Deaconess Medical Ct Inc Vacinas antivirais com imunogenicidade celular melhorada
RU2604815C2 (ru) 2009-02-02 2016-12-10 ГлаксоСмитКлайн Байолоджикалз с.а. Нуклеинокислотные и аминокислотные последовательности аденовируса обезьян, векторы, содержащие указанные последовательности, и их применение
WO2010085984A1 (en) 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2010096561A1 (en) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic hiv/siv gag proteins and uses thereof
CN105399833B (zh) 2010-01-04 2019-09-06 Kj 生物科学有限公司 用于疫苗和诊断学的Dps融合蛋白
EP2529010B1 (en) 2010-01-28 2017-04-19 Bavarian Nordic A/S Vaccinia virus mutants containing the major genomic deletions of mva
EP4226935A3 (en) 2010-08-31 2023-09-06 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies
BR112013014712B1 (pt) 2010-12-14 2021-03-02 The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services primeiro e segundo vetores de adenovírus recombinantes
CN103945864A (zh) * 2011-04-25 2014-07-23 先进生物学实验室股份有限公司 截短的hiv包膜蛋白(env)、其相关方法和组合物
WO2013036791A2 (en) 2011-09-09 2013-03-14 Beth Israel Deaconess Medical Center, Inc. Modified adenoviral vectors and methods of treatment using same
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
WO2013040766A1 (zh) * 2011-09-21 2013-03-28 中国疾病预防控制中心性病艾滋病预防控制中心 可诱导针对hiv的广谱免疫应答的方法和疫苗
WO2013055908A1 (en) 2011-10-12 2013-04-18 The Scripps Research Institute An hiv-1 gp120 mini v3 loop and uses thereof
WO2014047261A1 (en) 2012-09-19 2014-03-27 Beth Israel Deaconess Medical Center, Inc. Viruses associated with immunodeficiency and enteropathy and methods using same
SG11201503864TA (en) 2012-11-16 2015-06-29 Beth Israel Hospital Recombinant adenoviruses and use thereof
MY187152A (en) 2013-01-07 2021-09-06 Beth Israel Deaconess Medical Ct Inc Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using same
WO2014124301A1 (en) 2013-02-07 2014-08-14 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
US9624510B2 (en) * 2013-03-01 2017-04-18 The Wistar Institute Adenoviral vectors comprising partial deletions of E3
US10376583B2 (en) 2013-09-30 2019-08-13 Beth Israel Deaconess Medical Center, Inc. Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator
US10716845B2 (en) * 2013-10-04 2020-07-21 Beth Israel Deaconess Medical Center, Inc. Stabilized human immunodeficiency virus (HIV) clade C envelope (Env) trimer vaccines and methods of using same
JP2017507672A (ja) * 2014-02-28 2017-03-23 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 複製型組み換えアデノウイルスベクター、組成物およびこれらの使用方法
US10400015B2 (en) 2014-09-04 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant HIV-1 envelope proteins and their use
LT3197489T (lt) 2014-09-26 2021-07-26 Beth Israel Deaconess Medical Center, Inc. Būdai ir kompozicijos, skirti indukuoti apsauginį imunitetą prieš žmogaus imunodeficito viruso infekciją
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
WO2016146844A1 (en) * 2015-03-18 2016-09-22 Janssen Vaccines & Prevention B.V. Assays for recombinant expression systems
RS62360B1 (sr) 2015-12-15 2021-10-29 Janssen Vaccines & Prevention Bv Antigeni, vektori i sastavi virusa humane imunodeficijencije, i postupci njihove primene
EP3471765B1 (en) 2016-06-16 2024-04-24 Janssen Vaccines & Prevention B.V. Hiv vaccine formulation
US10307477B2 (en) 2016-09-02 2019-06-04 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
MX2019002938A (es) 2016-09-15 2019-10-15 Janssen Vaccines & Prevention Bv Mutaciones estebilizantes de trimeros de proteinas de la envoltura del vih.
DE102018124348A1 (de) 2018-10-02 2020-04-02 Haver & Boecker Ohg Füllkasten und Verfahren zum Füllen von Gebinden

Also Published As

Publication number Publication date
EA038974B1 (ru) 2021-11-17
HUE045993T2 (hu) 2020-01-28
RS62360B1 (sr) 2021-10-29
MX383507B (es) 2025-03-14
EP3964569A1 (en) 2022-03-09
DK3390430T3 (da) 2019-11-18
US11896663B2 (en) 2024-02-13
SG11201804411TA (en) 2018-06-28
CY1125387T1 (el) 2023-03-24
TWI792091B (zh) 2023-02-11
JP6510149B2 (ja) 2019-05-08
JP2019505188A (ja) 2019-02-28
EP3584252A1 (en) 2019-12-25
US10973907B2 (en) 2021-04-13
US20170165355A1 (en) 2017-06-15
DK3584252T3 (da) 2021-11-15
PH12018501047A1 (en) 2018-12-17
AU2019203468A1 (en) 2019-06-06
CA3008542A1 (en) 2017-06-22
IL259942A (en) 2018-07-31
SI3390430T1 (sl) 2019-12-31
HRP20211566T1 (hr) 2022-03-04
EP3584252B1 (en) 2021-08-25
CA3008542C (en) 2020-06-02
TW201734210A (zh) 2017-10-01
CY1122705T1 (el) 2021-03-12
PL3390430T3 (pl) 2020-03-31
ME03545B (me) 2020-07-20
HRP20191902T1 (hr) 2020-01-24
CN108368157A (zh) 2018-08-03
MD3390430T2 (ro) 2019-12-31
RS59447B1 (sr) 2019-11-29
MA47522A (fr) 2021-05-05
BR112018011122A2 (pt) 2018-11-21
SMT202100623T1 (it) 2022-01-10
PT3390430T (pt) 2019-11-20
MA44059A (fr) 2018-10-24
IL259942B (en) 2022-12-01
MX2021006931A (es) 2021-07-07
IL259942B2 (en) 2023-04-01
JP2019146574A (ja) 2019-09-05
US20190321462A1 (en) 2019-10-24
ES2753854T3 (es) 2020-04-14
MA47522B1 (fr) 2021-11-30
EA201891415A8 (ru) 2019-10-31
ZA201803978B (en) 2021-05-26
WO2017102929A1 (en) 2017-06-22
AU2019203468B2 (en) 2020-05-21
MX2018007198A (es) 2018-08-01
US10369214B2 (en) 2019-08-06
US20210220468A1 (en) 2021-07-22
EP3390430B1 (en) 2019-08-28
LT3390430T (lt) 2019-11-25
AU2016369326B2 (en) 2019-02-21
PL3584252T3 (pl) 2022-01-10
EA201891415A1 (ru) 2018-11-30
MA44059B1 (fr) 2019-11-29
HUE055916T2 (hu) 2021-12-28
KR20180086207A (ko) 2018-07-30
LT3584252T (lt) 2021-09-27
EP3390430A1 (en) 2018-10-24
MD3584252T2 (ro) 2022-01-31
ES2898271T3 (es) 2022-03-04
CN108368157B (zh) 2022-04-15
SMT201900629T1 (it) 2020-01-14
CN114686495A (zh) 2022-07-01
AU2016369326A1 (en) 2018-06-07
JP6959289B2 (ja) 2021-11-02
SG10202109457RA (en) 2021-10-28
TWI707039B (zh) 2020-10-11
MA55825A (fr) 2022-03-09
TW202106701A (zh) 2021-02-16

Similar Documents

Publication Publication Date Title
ZA201803978B (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
ZA201803783B (en) Human immunodeficiency virus neutralizing antibodies
IL257628A (en) Methods and compositions for stealth virus antibody vectors
IL263818A (en) Antibodies against Zika virus and methods of use
ZA201703163B (en) Rna guided eradication of human jc virus and other polyomaviruses
IL286265A (en) A new tilapia virus and its uses
IL265833A (en) Novel hla hpv16 unrestricted t-cell compositions, compositions and methods for their use
IL267673B1 (en) Broadly neutralizing antibodies against hiv-1 and methods of using them
IL272834A (en) Compositions of amantadine, their preparation, and methods of use
SG11201704942QA (en) Dengue virus vaccine compositions and methods of use thereof
ZA201906326B (en) Analogs of deutetrabenazine, their preparation and use
IL258238B (en) Hiv antibody compositions and methods of use
PT3584252T (pt) Antígenos, vetores, composições para o vírus da imunodeficiência humana e métodos da sua utilização
PT3390441T (pt) Anticorpos neutralizantes do vírus da imunodeficiência humana
GB201706600D0 (en) Virus preparations